
Please try another search
(Reuters) - Novavax (NASDAQ:NVAX) Inc said on Wednesday it had filed an application with Britain's drugs regulator for the authorization of its COVID-19 vaccine among adolescents aged 12 and older.
Britain had in February cleared the two-dose vaccine, Nuvaxovid, for use in adults amid a spike in cases fueled by the Omicron variant of the coronavirus.
Novavax's submission includes data from a late-stage trial in the United States, where the vaccine showed 80% efficacy among adolescents when Delta was the dominant variant in the country.
The drugmaker in late January filed for emergency use authorization of its COVID-19 shot for adults in the United States.
The U.S. Food and Drug Administration plans to hold several meetings of its outside panel of experts in June to discuss authorization requests submitted by multiple COVID-19 vaccine manufacturers including Novavax.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.